PLG and breast cancer: For example, Ranson et al. show that the aggressive, triple-negative metastatic breast cancer cell line MDA-MB-231 has a higher plasminogen binding capacity and cell surface plasmin generation relative to non-metastatic breast cancer cells (MCF-7 and T47D), suggesting that the increased expression of plasminogen receptors on breast cancer cells promotes its metastatic potential [89].